SCHEMBL4986527

SCHEMBL4986527

O=C(O)c1cccn(Cc2ccccc2-c2ccccc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.47
BRD2 P25440 1/20 0.47
BRD3 Q15059 1/20 0.47
BRDT Q58F21 1/20 0.47
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 1/20 0.46
MCL1 Q07820 1/20 0.46
BAD Q92934 1/20 0.46
RXFP1 Q9HBX9 2/20 0.44
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
HNF4A P41235 1/20 0.44
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4986221 0.92 LIPG (0.49) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4996274 0.88 PTGER3 (0.43) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4994721 0.86 CYP1A2 (0.44) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4438770 0.85 MAPT (0.53) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4992971 0.85 PTGER3 (0.48) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4553891 0.83 MCL1 (0.49) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4996102 0.82 BRD4 (0.44) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4994006 0.81 HDAC3 (0.56) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4990176 0.81 PTGER3 (0.60) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4993830 0.80 BRD4 (0.57) BRD4BRD2BRD3BRDTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 BRD4 2776/4885BRD2 4008/4885BRD3 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.